China National Pharmaceutical, also known as Sinopharm, is the parent of the drugmaker and had in 2021 decided against a possible privatisation of China TCM
PHOTO
China National Pharmaceutical Group has revived a take-private bid for China Traditional Chinese Medicine Holdings, valuing the Hong-Kong listed drugmaker at HK$23.16 billion ($2.96 billion).
China National Pharmaceutical, also known as Sinopharm, is the parent of the drugmaker and had in 2021 decided against a possible privatisation of China TCM. ($1 = 7.8215 Hong Kong dollars)
(Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun Koyyur)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
